Acadia Pharmaceuticals advances its serotonin 5-HT₂A inverse agonist, remlifanserin (ACP-204), into the final phases of clinical testing as …
Acadia Pharmaceuticals advances its serotonin 5-HT₂A inverse agonist, remlifanserin (ACP-204), into the final phases of clinical testing as …
A pioneering personalized cancer vaccine, designed using tumor-specific neoantigens, has achieved remission in all nine advanced kidney cancer …
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) modernizes its clinical trial framework with major updates to …
New clinical-stage anti-obesity therapies began breaking ground—designed not just to shed pounds, but to retain muscle, offering a …
Uvax Bio elevated Chief Business Officer Kevin O’Neill to Interim CEO following the departure of Ji Li, Ph.D., …
Novartis confirmed its acquisition of Anthos Therapeutics for up to $3.1 billion—securing a promising Phase III-stage anticoagulant aimed at …
Parexel reveals strategic plans to ramp up its Indian operations—underscoring India’s emerging prominence as a critical node in …
On February 1, 2025, the U.S. Food and Drug Administration (FDA) approved Eli Lilly’s lebrikizumab, marking the first …
Johnson & Johnson discontinues three neuroscience programs—including the sleep-focused seltorexant—realigning its R&D priorities and signaling a strategic course …